Bias in reporting of randomised clinical trials in oncology

European Journal of Cancer

Volumn 61, Issue , 2016, Pages 29-35

  Vera Badillo, Francisco E ^a   Napoleone, Marc ^a   Krzyzanowska, Monika K ^a   Alibhai, Shabbir M H ^b   Chan, An Wen ^c   Ocana, Alberto ^d   Seruga, Bostjan ^e   Templeton, Arnoud J ^f   Amir, Eitan ^a   Tannock, Ian F ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d HOSPITAL GENERAL UNIVERSITARIO DE ALBACETE   (Spain)

^e UNIVERSITY OF LJUBLJANA   (Slovenia)

^f CANTONAL HOSPITAL ST GALLEN   (Switzerland)

Author keywords

Bias; Conflicts of interest; Randomised clinical trials; Spin

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; CANCER CHEMOTHERAPY; DRUG EFFICACY; DRUG INDICATION; DRUG MISUSE; DRUG SAFETY; HUMAN; OFF LABEL DRUG USE; ONCOLOGY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); STATISTICAL BIAS; SYSTEMIC THERAPY; TREATMENT OUTCOME; CONFLICT OF INTEREST; ETHICS; FINANCIAL MANAGEMENT; NEOPLASMS; STANDARDS;

ANTINEOPLASTIC AGENTS; BIAS (EPIDEMIOLOGY); CAPITAL FINANCING; CONFLICT OF INTEREST; HUMANS; MEDICAL ONCOLOGY; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84964685786     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2016.03.066     Document Type: Article

References (18)

1. E.S. Antonarakis, and M.A. Eisenberger Phase III trials with docetaxel-based combinations for metastatic castration-resistant prostate cancer: time to learn from past experiences J Clin Oncol 31 14 2013 1709 1712
2. A. Hrobjartsson, and P.C. Gotzsche Powerful spin in the conclusion of Wampold et al.'s re-analysis of placebo versus no-treatment trials despite similar results as in original review J Clin Psychol 63 4 2007 373 377
3. C.A. Marco, and G.L. Larkin Research ethics: ethical issues of data reporting and the quest for authenticity Acad Emerg Med 7 6 2000 691 694
4. F.E. Vera-Badillo, R. Shapiro, A. Ocana, E. Amir, and I.F. Tannock Bias in reporting of end points of efficacy and toxicity in randomized, clinical trials for women with breast cancer Ann Oncol 24 5 2013 1238 1244
5. I. Boutron, D.G. Altman, S. Hopewell, F. Vera-Badillo, I. Tannock, and P. Ravaud Impact of spin in the abstracts of articles reporting results of randomized controlled trials in the field of cancer: the SPIIN randomized controlled trial J Clin Oncol 32 36 2014 4120 4126
6. D. Junger The rhetoric of research. Embrace scientific rhetoric for its power BMJ 311 6996 1995 61
7. I. Pitrou, I. Boutron, N. Ahmad, and P. Ravaud Reporting of safety results in published reports of randomized controlled trials Arch Intern Med 169 19 2009 1756 1761
8. J.S. Ross, K.P. Hill, D.S. Egilman, and H.M. Krumholz Guest authorship and ghostwriting in publications related to rofecoxib: a case study of industry documents from rofecoxib litigation JAMA 299 15 2008 1800 1812
9. J.P. Ioannidis Limitations are not properly acknowledged in the scientific literature J Clin Epidemiol 60 4 2007 324 329
10. I. Boutron, S. Dutton, P. Ravaud, and D.G. Altman Reporting and interpretation of randomized controlled trials with statistically nonsignificant results for primary outcomes JAMA 303 20 2010 2058 2064
11. H.C. Barry, M.H. Ebell, A.F. Shaughnessy, D.C. Slawson, and F. Nietzke Family physicians' use of medical abstracts to guide decision making: style or substance? J Am Board Fam Pract 14 6 2001 437 442
12. O. Berwanger, R.A. Ribeiro, A. Finkelsztejn, M. Watanabe, E.A. Suzumura, B.B. Duncan, and et al. The quality of reporting of trial abstracts is suboptimal: survey of major general medical journals J Clin Epidemiol 62 4 2009 387 392
13. D.A. Reed, D.A. Cook, T.J. Beckman, R.B. Levine, D.E. Kern, and S.M. Wright Association between funding and quality of published medical education research JAMA 298 9 2007 1002 1009
14. S. Saint, D.A. Christakis, S. Saha, J.G. Elmore, D.E. Welsh, P. Baker, and et al. Journal reading habits of internists J Gen Intern Med 15 12 2000 881 884
15. B. Als-Nielsen, W. Chen, C. Gluud, and L.L. Kjaergard Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events? JAMA 290 7 2003 921 928
16. L. Manzoli, G. Salanti, C. De Vito, A. Boccia, J.P. Ioannidis, and P. Villari Immunogenicity and adverse events of avian influenza A H5N1 vaccine in healthy adults: multiple-treatments meta-analysis Lancet Infect Dis 9 8 2009 482 492
17. M. Friedberg, B. Saffran, T.J. Stinson, W. Nelson, and C.L. Bennett Evaluation of conflict of interest in economic analyses of new drugs used in oncology JAMA 282 15 1999 1453 1457
18. D.G. Haller, and S. Cannistra Providing protocol information for Journal of Clinical Oncology readers: what practicing clinicians need to know J Clin Oncol 29 9 2011 1091